Skip to main content
SpringerLink
Log in

Novel Small Molecule Inhibitors of Cancer Stem Cell Signaling Pathways

Stem Cell Reviews and Reports volume 11, pages 909–918 (2015)Cite this article

Abstract

The main aim of oncologists worldwide is to understand and then intervene in the primary tumor initiation and propagation mechanisms. This is essential to allow targeted elimination of cancer cells without altering normal mitotic cells. Currently, there are two main rival theories describing the process of tumorigenesis. According to the Stochastic Model, potentially any cell, once defunct, is capable of initiating carcinogenesis. Alternatively the Cancer Stem Cell (CSC) Model posits that only a small fraction of undifferentiated tumor cells are capable of triggering carcinogenesis. Like healthy stem cells, CSCs are also characterized by a capacity for self-renewal and the ability to generate differentiated progeny, possibly mediating treatment resistance, thus leading to tumor recurrence and metastasis. Moreover, molecular signaling profiles are similar between CSCs and normal stem cells, including Wnt, Notch and Hedgehog pathways. Therefore, development of novel chemotherapeutic agents and proteins (e.g., enzymes and antibodies) specifically targeting CSCs are attractive pharmaceutical candidates. This article describes small molecule inhibitors of stem cell pathways Wnt, Notch and Hedgehog, and their recent chemotherapy clinical trials.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

USD 39.95

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Fig. 1

References

  1. Reya, T., Morrison, S. J., Clarke, M. F., & Weissman, I. L. (2001). Stem cells, cancer, and cancer stem cells. Nature, 414, 105–11.

    Article  CAS  PubMed  Google Scholar 

  2. Shackleton, M., Quintana, E., Fearon, E. R., & Morrison, S. J. (2009). Heterogeneity in cancer: cancer stem cells versus clonal evolution. Cell, 138, 822–9.

    Article  CAS  PubMed  Google Scholar 

  3. Dick, J. E. (2008). Stem cell concepts renew cancer research. Blood, 112, 4793–807.

    Article  CAS  PubMed  Google Scholar 

  4. Iyer, K. S., & Saksena, V. N. (1970). A stochastic model for the growth of cells in cancer. Biometrics, 26, 401–10.

    Article  CAS  PubMed  Google Scholar 

  5. Odoux, C., Fohrer, H., Hoppo, T., et al. (2008). A stochastic model for cancer stem cell origin in metastatic colon cancer. Cancer Research, 68, 6932–41.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  6. Lapidot, T., Sirard, C., Vormoor, J., et al. (1994). A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature, 367, 645–8.

    Article  CAS  PubMed  Google Scholar 

  7. Bonnet, D., & Dick, J. E. (1997). Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nature Medicine, 3, 730–7.

    Article  CAS  PubMed  Google Scholar 

  8. Al-Hajj, M., & Clarke, M. F. (2004). Self-renewal and solid tumor stem cells. Oncogene, 23, 7274–82.

    Article  CAS  PubMed  Google Scholar 

  9. Takebe, N., & Ivy, S. P. (2010). Controversies in cancer stem cells: targeting embryonic signaling pathways. Clinical Cancer Research, 16, 3106–12.

    Article  CAS  PubMed  Google Scholar 

  10. Wang, W. K., Quan, Y., Fu, Q. B., et al. (2014). Dynamics between Cancer Cell Subpopulations Reveals a Model Coordinating with Both Hierarchical and Stochastic Concepts. PLoS One, 9, 1.

  11. Takebe, N., Harris, P. J., Warren, R. Q., & Ivy, S. P. (2011). Targeting cancer stem cells by inhibiting Wnt, Notch, and Hedgehog pathways. Nature Reviews. Clinical Oncology, 8, 97–106.

    Article  CAS  PubMed  Google Scholar 

  12. Klaus, A., & Birchmeier, W. (2008). Wnt signalling and its impact on development and cancer. Nature Reviews Cancer, 8, 387–98.

    Article  CAS  PubMed  Google Scholar 

  13. Seifert, J. R. K., & Mlodzik, M. (2007). Frizzled/PCP signalling: a conserved mechanism regulating cell polarity and directed motility. Nature Reviews Genetics, 8, 126–38.

    Article  CAS  PubMed  Google Scholar 

  14. Vermeulen, L., De Sousa, E. M. F., van der Heijden, M., et al. (2010). Wnt activity defines colon cancer stem cells and is regulated by the microenvironment. Nature Cell Biology, 12, 468–76.

    Article  CAS  PubMed  Google Scholar 

  15. Simon, M., Grandage, V. L., Linch, D. C., & Khwaja, A. (2005). Constitutive activation of the Wnt/beta-catenin signalling pathway in acute myeloid leukaemia. Oncogene, 24, 2410–20.

    Article  CAS  PubMed  Google Scholar 

  16. Zhao, C., Blum, J., Chen, A., Kwon, H. Y., Jung, S. H., Cook, J. M., Lagoo, A., & Reya, T. (2007). Loss of beta-catenin impairs the renewal of normal and CML stem cells in vivo. Cancer Cell, 12, 528–41.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  17. Ooi, C. H., Ivanova, T., Wu, J., et al. (2009). Oncogenic pathway combinations predict clinical prognosis in gastric cancer. PLoS Genetics, 5, e1000676.

    Article  PubMed Central  PubMed  Google Scholar 

  18. MacDonald, B. T., Tamai, K., & He, X. (2009). Wnt/beta-catenin signaling: components, mechanisms, and diseases. Developmental Cell, 17, 9–26.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  19. Takemaru, K. I., & Moon, R. T. (2000). The transcriptional coactivator CBP interacts with beta-catenin to activate gene expression. Journal of Cell Biology, 149, 249–54.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  20. Hecht, A., Vleminckx, K., Stemmler, M. P., van Roy, F., & Kemler, R. (2000). The p300/CBP acetyltransferases function as transcriptional coactivators of beta-catenin in vertebrates. EMBO Journal, 19, 1839–50.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  21. de Sousa, E. M. F., Vermeulen, L., Richel, D., & Medema, J. P. (2011). Targeting Wnt signaling in colon cancer stem cells. Clinical Cancer Research, 17, 647–53.

    Article  PubMed  Google Scholar 

  22. Chen, B., Dodge, M. E., Tang, W., et al. (2009). Small molecule-mediated disruption of Wnt-dependent signaling in tissue regeneration and cancer. Nature Chemical Biology, 5, 100–7.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  23. Waaler, J., Machon, O., von Kries, J. P., et al. (2011). Novel synthetic antagonists of canonical Wnt signaling inhibit colorectal cancer cell growth. Cancer Research, 71, 197–205.

    Article  CAS  PubMed  Google Scholar 

  24. Chen, Z., Venkatesan, A. M., Dehnhardt, C. M., et al. (2009). 2,4-Diamino-quinazolines as inhibitors of beta-catenin/Tcf-4 pathway: potential treatment for colorectal cancer. Bioorganic & Medicinal Chemistry Letters, 19, 4980–3.

    Article  CAS  Google Scholar 

  25. Trosset, J. Y., Dalvit, C., Knapp, S., et al. (2006). Inhibition of protein-protein interactions: the discovery of druglike beta-catenin inhibitors by combining virtual and biophysical screening. Proteins, 64, 60–7.

    Article  CAS  PubMed  Google Scholar 

  26. Huang, S. M., Mishina, Y. M., Liu, S., et al. (2009). Tankyrase inhibition stabilizes axin and antagonizes Wnt signalling. Nature, 461, 614–20.

    Article  CAS  PubMed  Google Scholar 

  27. Emami, K. H., Nguyen, C., Ma, H., et al. (2004). A small molecule inhibitor of beta-catenin/CREB-binding protein transcription [corrected]. Proceedings of the National Academy of Sciences of the United States of America, 101, 12682–7.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  28. Shan, J., Shi, D. L., Wang, J., & Zheng, J. (2005). Identification of a specific inhibitor of the dishevelled PDZ domain. Biochemistry, 44, 15495–503.

    Article  CAS  PubMed  Google Scholar 

  29. Takahashi-Yanaga, F., & Kahn, M. (2010). Targeting Wnt signaling: can we safely eradicate cancer stem cells? Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 16, 3153–62.

    Article  CAS  Google Scholar 

  30. Boon, E. M., Keller, J. J., Wormhoudt, T. A., Giardiello, F. M., Offerhaus, G. J., van der Neut, R., & Pals, S. T. (2004). Sulindac targets nuclear beta-catenin accumulation and Wnt signalling in adenomas of patients with familial adenomatous polyposis and in human colorectal cancer cell lines. British Journal of Cancer, 90, 224–9.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  31. Ingham, P. W., & McMahon, A. P. (2001). Hedgehog signaling in animal development: paradigms and principles. Genes & Development, 15, 3059–87.

    Article  CAS  Google Scholar 

  32. Varjosalo, M., & Taipale, J. (2008). Hedgehog: functions and mechanisms. Genes & Development, 22, 2454–72.

    Article  CAS  Google Scholar 

  33. Amakye, D., Jagani, Z., & Dorsch, M. (2013). Unraveling the therapeutic potential of the Hedgehog pathway in cancer. Nature Medicine, 19, 1410–22.

    Article  CAS  PubMed  Google Scholar 

  34. Taipale, J., Chen, J. K., Cooper, M. K., Wang, B., Mann, R. K., Milenkovic, L., Scott, M. P., & Beachy, P. A. (2000). Effects of oncogenic mutations in Smoothened and Patched can be reversed by cyclopamine. Nature, 406, 1005–9.

    Article  CAS  PubMed  Google Scholar 

  35. Wu, J. Y., Xu, X. F., Xu, L., Niu, P. Q., Wang, F., Hu, G. Y., Wang, X. P., & Guo, C. Y. (2011). Cyclopamine blocked the growth of colorectal cancer SW116 cells by modulating some target genes of Gli1 in vitro. Hepato-Gastroenterology, 58, 1511–8.

    CAS  PubMed  Google Scholar 

  36. LoRusso, P. M., Rudin, C. M., Borad, M. J., et al. (2008). A first-in-human, first-in-class, phase (ph) I study of systemic Hedgehog (Hh) pathway antagonist, GDC-0449, in patients (pts) with advanced solid tumors. Journal of Clinical Oncology, 26, 15.

  37. Stein, A., & Bokemeyer, C. (2014). How to select the optimal treatment for first line metastatic colorectal cancer. World J Gastroenterol, 20(4), 899–907.

  38. Lin, T. L., & Matsui, W. (2012). Hedgehog pathway as a drug target: smoothened inhibitors in development. OncoTargets and Therapy, 5, 47–58.

  39. Jamieson, C., Cortes, J. E., Oehler, V., et al. (2011). Phase 1 dose-escalation study of PF-04449913, an oral hedgehog (Hh) inhibitor, in patients with select hematologic malignancies. Blood, 118, 195–6.

  40. Artavanis-Tsakonas, S., Rand, M., & Lake, R. (1999). Notch signaling: cell fate control and signal integration in development. Science, 284, 770–6.

  41. Reedijk, M., Odorcic, S., Zhang, H., et al. (2008). Activation of Notch signaling in human colon adenocarcinoma. International Journal of Oncology, 33, 1223–9.

  42. Meng, R. D., Shelton, C. C., Li, Y. M., Qin, L. X., Notterman, D., Paty, P. B., & Schwartz, G. K. (2009). gamma-Secretase inhibitors abrogate oxaliplatin-induced activation of the Notch-1 signaling pathway in colon cancer cells resulting in enhanced chemosensitivity. Cancer Research, 69, 573–82.

  43. Huynh, C., Poliseno, L., Segura, M. F., et al. (2011). The Novel Gamma Secretase Inhibitor RO4929097 Reduces the Tumor Initiating Potential of Melanoma. PLoS One, 6(9), e25264.

  44. Deangelo, D. J., Stone, R. M., Silverman, L. B., et al. (2006). A phase I clinical trial of the notch inhibitor MK-0752 in patients with T-cell acute lymphoblastic leukemia/lymphoma (T-ALL) and other leukemias. Journal of Clinical Oncology, 24, 357s-s.

  45. Fouladi, M., Stewart, C. F., Olson, J., et al. (2011). Phase I trial of MK-0752 in children with refractory CNS malignancies: a pediatric brain tumor consortium study. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, 29, 3529–34.

    Article  CAS  Google Scholar 

  46. Ridgway, J., Zhang, G., Wu, Y., et al. (2006). Inhibition of Dll4 signalling inhibits tumour growth by deregulating angiogenesis. Nature, 444, 1083–7.

    Article  CAS  PubMed  Google Scholar 

  47. Rudge, J. S., Thurston, G., Davis, S., Papadopoulos, N., Gale, N., Wiegand, S. J., & Yancopoulos, G. D. (2005). VEGF trap as a novel antiangiogenic treatment currently in clinical trials for cancer and eye diseases, and VelociGene- based discovery of the next generation of angiogenesis targets. Cold Spring Harbor Symposia on Quantitative Biology, 70, 411–8.

    Article  CAS  PubMed  Google Scholar 

  48. Noguera-Troise, I., Daly, C., Papadopoulos, N. J., et al. (2006). Blockade of Dll4 inhibits tumour growth by promoting non-productive angiogenesis. Nature, 444, 1032–7.

    Article  CAS  PubMed  Google Scholar 

  49. Fischer, M., Yen, W. C., Kapoun, A. M., Wang, M., O’Young, G., Lewicki, J., Gurney, A., & Hoey, T. (2011). Anti-DLL4 inhibits growth and reduces tumor-initiating cell frequency in colorectal tumors with oncogenic KRAS mutations. Cancer Research, 71, 1520–5.

    Article  CAS  PubMed  Google Scholar 

  50. Visvader, J. E., & Lindeman, G. J. (2008). Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nature Reviews Cancer, 8, 755–68.

    Article  CAS  PubMed  Google Scholar 

  51. Harbinski, F., Craig, V. J., Sanghavi, S., et al. (2012). Rescue screens with secreted proteins reveal compensatory potential of receptor tyrosine kinases in driving cancer growth. Cancer Discovery, 2, 948–59.

    Article  CAS  PubMed  Google Scholar 

  52. Burrell, R. A., McGranahan, N., Bartek, J., & Swanton, C. (2013). The causes and consequences of genetic heterogeneity in cancer evolution. Nature, 501, 338–45.

    Article  CAS  PubMed  Google Scholar 

  53. Lagasse, E. (2008). Cancer stem cells with genetic instability: the best vehicle with the best engine for cancer. Gene Therapy, 15, 136–42.

    Article  CAS  PubMed  Google Scholar 

  54. Miura, M., Miura, Y., Padilla-Nash, H. M., et al. (2006). Accumulated chromosomal instability in murine bone marrow mesenchymal stem cells leads to malignant transformation. Stem Cells, 24, 1095–103.

    Article  PubMed  Google Scholar 

  55. Shiras, A., Chettiar, S. T., Shepal, V., Rajendran, G., Prasad, G. R., & Shastry, P. (2007). Spontaneous transformation of human adult nontumorigenic stem cells to cancer stem cells is driven by genomic instability in a human model of glioblastoma. Stem Cells, 25, 1478–89.

    Article  CAS  PubMed  Google Scholar 

  56. Lee, H. J., Wang, N. X., Shi, D. L., & Zheng, J. J. (2009). Sulindac inhibits canonical Wnt signaling by blocking the PDZ domain of the protein dishevelled. Angewandte Chemie-International Edition, 48, 6448–52.

    Article  CAS  Google Scholar 

  57. Taipale, J., Chen, J. K., Cooper, M. K., Wang, B. L., Mann, R. K., Milenkovic, L., Scott, M. P., & Beachy, P. A. (2000). Effects of oncogenic mutations in smoothened and patched can be reversed by cyclopamine. Nature, 406, 1005–9.

    Article  CAS  PubMed  Google Scholar 

  58. Gajjar, A., Stewart, C. F., Ellison, D. W., et al. (2013). Phase I study of vismodegib in children with recurrent or refractory medulloblastoma: a pediatric brain tumor consortium study. Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 19, 6305–12.

    Article  CAS  Google Scholar 

  59. LoRusso, P. (2009). Targeting the hedgehog pathway in medulloblastoma and advanced basal cell cancer therapy. Cancer Biology & Therapy, 8, v-vi.

  60. Barginear, M., Clotfelter, A., & Van Poznak, C. (2009). Markers of bone metabolism in women receiving aromatase inhibitors for early-stage breast cancer. Clinical Breast Cancer, 9, 72–6.

    Article  CAS  PubMed  Google Scholar 

  61. Jimeno, A., Weiss, G. J., Miller, W. H., et al. (2013). Phase I study of the hedgehog pathway inhibitor IPI-926 in adult patients with solid tumors. Clinical Cancer Research, 19, 2766–74.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  62. Williams, J. A. (2003). Hedgehog signaling pathway as a target for therapeutic intervention in basal cell carcinoma. Drug News & Perspectives, 16, 657–62.

    Article  CAS  Google Scholar 

  63. Barginear, M. F., Leung, M., & Budman, D. R. (2009). The hedgehog pathway as a therapeutic target for treatment of breast cancer. Breast Cancer Research and Treatment, 116, 239–46.

    Article  CAS  PubMed  Google Scholar 

  64. Rodon, J., Tawbi, H. A., Thomas, A. L., et al. (2014). A phase I, multicenter, open-label, first-in-human, dose-escalation study of the oral smoothened inhibitor Sonidegib (LDE225) in patients with advanced solid tumors. Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 20, 1900–9.

    Article  CAS  Google Scholar 

  65. Schott, A. F., Landis, M. D., Dontu, G., et al. (2013). Preclinical and clinical studies of gamma secretase inhibitors with docetaxel on human breast tumors. Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 19, 1512–24.

    Article  CAS  Google Scholar 

  66. LoConte, N. K., Razak, A. R., Ivy, P., et al. (2015). A multicenter phase 1 study of gamma -secretase inhibitor RO4929097 in combination with capecitabine in refractory solid tumors. Investigational New Drugs, 33, 169–76.

    Article  CAS  PubMed  Google Scholar 

  67. Diaz-Padilla, I., Wilson, M. K., Clarke, B. A., et al. (2015). A phase II study of single-agent RO4929097, a gamma-secretase inhibitor of Notch signaling, in patients with recurrent platinum-resistant epithelial ovarian cancer: a study of the Princess Margaret, Chicago and California phase II consortia. Gynecologic oncology.

  68. De Jesus-Acosta, A., Laheru, D., Maitra, A., et al. (2014). A phase II study of the gamma secretase inhibitor RO4929097 in patients with previously treated metastatic pancreatic adenocarcinoma. Investigational New Drugs, 32, 739–45.

    Article  PubMed Central  PubMed  Google Scholar 

  69. Richter, S., Bedard, P. L., Chen, E. X., et al. (2014). A phase I study of the oral gamma secretase inhibitor R04929097 in combination with gemcitabine in patients with advanced solid tumors (PHL-078/CTEP 8575). Investigational New Drugs, 32, 243–9.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  70. Tolcher, A. W., Messersmith, W. A., Mikulski, S. M., et al. (2012). Phase I study of RO4929097, a gamma secretase inhibitor of Notch signaling, in patients with refractory metastatic or locally advanced solid tumors. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, 30, 2348–53.

    Article  CAS  Google Scholar 

  71. Sahebjam, S., Bedard, P. L., Castonguay, V., et al. (2013). A phase I study of the combination of ro4929097 and cediranib in patients with advanced solid tumours (PJC-004/NCI 8503). British Journal of Cancer, 109, 943–9.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  72. Olsauskas-Kuprys, R., Zlobin, A., & Osipo, C. (2013). Gamma secretase inhibitors of Notch signaling. OncoTargets and Therapy, 6, 943–55.

    PubMed Central  CAS  PubMed  Google Scholar 

  73. Egloff, A. M., & Grandis, J. R. (2012). Molecular pathways: context-dependent approaches to Notch targeting as cancer therapy. Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 18, 5188–95.

    Article  CAS  Google Scholar 

  74. Tong, G., Wang, J. S., Sverdlov, O., et al. (2012). Multicenter, randomized, double-blind, placebo-controlled, single-ascending dose study of the oral gamma-secretase inhibitor BMS-708163 (Avagacestat): tolerability profile, pharmacokinetic parameters, and pharmacodynamic markers. Clinical Therapeutics, 34, 654–67.

    Article  CAS  PubMed  Google Scholar 

  75. Gurney, A., Axelrod, F., Bond, C. J., et al. (2012). Wnt pathway inhibition via the targeting of Frizzled receptors results in decreased growth and tumorigenicity of human tumors. Proceedings of the National Academy of Sciences of the United States of America, 109, 11717–22.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  76. Yabuuchi, S., Pai, S. G., Campbell, N. R., et al. (2013). Notch signaling pathway targeted therapy suppresses tumor progression and metastatic spread in pancreatic cancer. Cancer Letters, 335, 41–51.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  77. Messersmith, W. A., Shapiro, G. I., Cleary, J. M., et al. (2015). A Phase I, dose-finding study in patients with advanced solid malignancies of the oral gamma-secretase inhibitor PF-03084014. Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 21, 60–7.

    Article  CAS  Google Scholar 

  78. Smith, D. C., Eisenberg, P. D., Manikhas, G., et al. (2014). A phase I dose escalation and expansion study of the anticancer stem cell agent demcizumab (anti-DLL4) in patients with previously treated solid tumors. Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 20, 6295–303.

    Article  CAS  Google Scholar 

  79. Zemskova, M., Wechter, W., Bashkirova, S., Chen, C. S., Reiter, R., & Lilly, M. B. (2006). Gene expression profiling in R-flurbiprofen-treated prostate cancer: R-Flurbiprofen regulates prostate stem cell antigen through activation of AKT kinase. Biochemical Pharmacology, 72, 1257–67.

    Article  CAS  PubMed  Google Scholar 

  80. Le, P. N., McDermott, J. D., & Jimeno, A. (2015). Targeting the Wnt pathway in human cancers: therapeutic targeting with a focus on OMP-54 F28. Pharmacology & Therapeutics, 146, 1–11.

    Article  CAS  Google Scholar 

  81. Previs, R. A., Coleman, R. L., Harris, A. L., & Sood, A. K. (2015). Molecular pathways: translational and therapeutic implications of the notch signaling pathway in cancer. Clinical Cancer Research, 21, 955–61.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

Authors are thankful for financial support provided through the grant “Analysis of gene expression for different stages of colorectal cancer” (‘Programme-targeted funding 2014–2017’; Government of Republic of Kazakhstan).

Author Contributions

All authors equally contributed to the design, literature analysis and writing of the manuscript.

Disclosure of Interest

The authors have no commercial, proprietary, or financial interest in the products or companies described in this article.

Author information

Authors and Affiliations

  1. Laboratory of Translational Medicine and Life Sciences Technologies, Centre for Life Sciences, Nazarbayev University, Unit 9, 53 Kabanbay batyr Ave., Astana, 010000, Kazakhstan

    Danysh Abetov, Zhanar Mustapova & Timur Saliev

  2. School of Medicine, Nazarbayev University, Unit 9, 53 Kabanbay batyr Ave., Astana, 010000, Kazakhstan

    Denis Bulanin

  3. Research Institute of Traumatology and Orthopedics, Astana, 010000, Kazakhstan

    Kanat Batyrbekov

  4. School of Science and Technology, Nazarbayev University, Unit 7, 53 Kabanbay batyr Ave., Astana, 010000, Kazakhstan

    Charles P. Gilman

Authors
  1. Danysh Abetov
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Zhanar Mustapova
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Timur Saliev
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Denis Bulanin
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Kanat Batyrbekov
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Charles P. Gilman
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Timur Saliev.

Rights and permissions

Reprints and Permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Abetov, D., Mustapova, Z., Saliev, T. et al. Novel Small Molecule Inhibitors of Cancer Stem Cell Signaling Pathways. Stem Cell Rev and Rep 11, 909–918 (2015). https://doi.org/10.1007/s12015-015-9612-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12015-015-9612-x

Keywords

search

Navigation